Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Announces Corporate Update and Reports First Quarter 2020 Financial Results
- Ongoing clinical programs remain on track with data readouts expected between 2020-21 - Progressing first- or best-in-class drug candidates with liquidity position of ~$1bn as of March 31, 2020 SAN DIEGO , May 7, 2020 /PRNewswire/ --  Arena Pharmaceuticals, Inc.
View HTML
Toggle Summary Arena Pharmaceuticals to Present at the Bank of America Securities Healthcare Conference on May 13
SAN DIEGO , May 6, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Preston Klassen , MD, MHS, the Company's Executive Vice President, Head of Research & Development, is scheduled to participate in a virtual fireside chat at the Bank of America Securities 2020
View HTML
Toggle Summary Arena Pharmaceuticals to Release First Quarter 2020 Financial Results and Provide Corporate Update on May 7
SAN DIEGO , April 30, 2020 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its first quarter 2020 financial results and provide a corporate update on Thursday, May 7, 2020 , after the close of the U.S. financial markets. The Company will host a question and answer session
View HTML
Toggle Summary Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , April 24, 2020 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on April 15, 2020 , the Compensation Committee of its Board of Directors granted inducement stock options to purchase an aggregate of 39,800 shares of its common stock to nine new employees
View HTML
Toggle Summary Arena Pharmaceuticals to Present at the 19th Annual Needham Virtual Healthcare Conference on April 14
SAN DIEGO , April 10, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , the Company's President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the 19th Annual Needham Healthcare Conference on Tuesday, April
View HTML
Toggle Summary Arena Pharmaceuticals Announces Positive Topline Data for New Development Program - Etrasimod Controlled-Release (CR)
- Etrasimod CR profile designed to retain etrasimod's rapid onset of action while further improving its potentially best-in-class, non-titrated, low intrinsic first-dose heart rate effect - Positive topline data from Phase 1 study demonstrated significant reduction in heart rate effect,
View HTML
Toggle Summary Arena Pharmaceuticals Names James C. Mullen as an Independent Senior Advisor
SAN DIEGO , March 30, 2020 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that James C. Mullen has agreed to serve as an independent senior advisor to the Company. "We are honored to have Jim as an advisor to Arena. In a rapidly evolving industry, and especially in
View HTML
Toggle Summary Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , March 18, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on March 12, 2020 , the Compensation Committee of its Board of Directors approved inducement stock options and inducement performance restricted stock units ("PRSUs") to new employees that
View HTML
Toggle Summary Arena Announces Management and Program Updates and Reports Fourth Quarter and Full-Year 2019 Financial Results
- Appoints Kevin R. Lind as President and Chief Executive Officer of Arena Neuroscience, Inc. - Appoints Laurie D. Stelzer as Executive Vice President and Chief Financial Officer of Arena - Expects to deliver up to eight major data readouts between 2020-21 and multiple INDs - Progressing first- or
View HTML
Toggle Summary Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Feb. 21, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on February 10, 2020 the Compensation Committee of its Board of Directors granted inducement stock options to purchase an aggregate of 132,100 shares of its common stock to 20 new employees. 
View HTML